![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHM9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3e739c5f065ee464e92b9a83c64b799e13fcc7f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/OncoResponse-Logo.png)
OncoResponse
OncoResponse develops a pipeline of immunomodulatory antibodies derived from elite responders’ immune systems. Its Lead program targets the M2-like TAMs in the tumor microenvironment.
Website
www.oncoresponseinc.comPartner
Wende HuttonInvestment
Series A